Biosimilar, Generic and Rx User Fees Rely On Different Adjusters For Needed Appropriations

Related Articles: 11

Elsevier Business Intelligence Publications

• Click an article headline for more information.
• Burgess Not Changing Conflict Of Interest Thinking Despite Flap Over Oral Contraceptive AC
  “The Pink Sheet” Jan. 23, 2012
• Accelerated Approval Could Expand As Alternative To Progressive Approval
  “The Pink Sheet” Jan. 23, 2012
• FDA, Industry Haggle Over Price For New User Fee Deal
  “The Gray Sheet” Jan. 16, 2012
• PDUFA V Action Heats Up On Hill With House Hearings In February
  “The Pink Sheet” DAILY Jan. 12, 2012
• Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation
  “The Pink Sheet” DAILY Dec. 19, 2011
• User Fee Triggers Require Care In Unfriendly Budget Environment, Ventimiglia Says
  “The Pink Sheet” Dec. 5, 2011
• FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees
  “The Pink Sheet” Nov. 28, 2011
• Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
  “The Pink Sheet” DAILY Sep. 22, 2011
• FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
  “The Pink Sheet” Jul. 18, 2011
• PDUFA Formula Could Better Incorporate Present Economic Conditions
  “The Pink Sheet” Apr. 18, 2011
• FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less
  “The Pink Sheet” Aug. 2, 2010

Topics Covered in this Article

• Click a keyword for related articles.
• General Topics
  PDUFA
  FDA
• Subjects
  Regulatory
  Pre-Market Regulation
  Drug Approval Standards
  Legislation
• Industries
  Biopharmaceuticals
• Regions
  North America
  United States